Roche sells chronic wound technology to SWITCH:
This article was originally published in Clinica
German company SWITCH Biotech has gained worldwide rights to a chronic woundcare delivery system from Roche Diagnostics. Developed by Boehringer Mannheim, the delivery system takes epithelial cells, including keratinocytes, attached to a collagen-based biodegradable microcarrier to form an ointment to seed over large chronic wounds. The delivery system greatly accelerates the skin healing process, according to Martinsried-based SWITCH.